<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">30465497</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>22</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1875-5453</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>21</Day>                    </PubDate>                </JournalIssue>                <Title>Current drug metabolism</Title>                <ISOAbbreviation>Curr. Drug Metab.</ISOAbbreviation>            </Journal>            <ArticleTitle>Iron oxide nanoparticles for breast cancer theranostics.</ArticleTitle>            <ELocationID EIdType="doi" ValidYN="Y">10.2174/1389200220666181122105043</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Breast cancer is the second leading cause of death in women worldwide. The extremely fast rate of metastasis and ability to develop resistance mechanism to all the conventional drugs make them very difficult to treat which are the causes of high morbidity and mortality of breast cancer patients. Scientists throughout the world have been focusing on the early detection of breast tumor so that treatment can be started at the very early stage. Moreover, conventional treatment processes such as chemotherapy, radiotherapy, and local surgery suffer from various limitations including toxicity, genetic mutation of normal cells, and spreading of cancer cells to healthy tissues. Therefore, new treatment regimens with minimum toxicity to normal cells need to be urgently developed.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Iron oxide nanoparticles have been widely used for targeting hyperthermia and imaging of breast cancer cells. They can be conjugated with drugs, proteins, enzymes, antibodies or nucleotides to deliver them to target organs, tissues or tumors using external magnetic field.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Iron oxide nanoparticles have been successfully used as theranostic agents for breast cancer both in vitro and in vivo. Furthermore, their functionalization with drugs or functional biomolecules enhance their drug delivery efficiency and reduces the systemic toxicity of drugs.</AbstractText>                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This review mainly focuses on the versatile applications of superparamagnetic iron oxide nanoparticles on the diagnosis, treatment, and detecting progress of breast cancer treatment. Their wide application is because of their excellent superparamagnetic, biocompatible and biodegradable properties.</AbstractText>                <CopyrightInformation>CopyrightÂ© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Shakil</LastName>                    <ForeName>Salman</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka-1342. Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hasan</LastName>                    <ForeName>Ashraful</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biochemistry and Molecular Biology, Jahangirnagar University, Savar, Dhaka-1342. Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sarker</LastName>                    <ForeName>Satya Ranjan</ForeName>                    <Initials>SR</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Biotechnology and Genetic Engineering, Jahangirnagar University, Savar, Dhaka-1342. Bangladesh.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>21</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>Netherlands</Country>            <MedlineTA>Curr Drug Metab</MedlineTA>            <NlmUniqueID>100960533</NlmUniqueID>            <ISSNLinking>1389-2002</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Iron oxide nanoparticles</Keyword>            <Keyword MajorTopicYN="N">MRI contrast agent</Keyword>            <Keyword MajorTopicYN="N">breast cancer</Keyword>            <Keyword MajorTopicYN="N">hyperthermia</Keyword>            <Keyword MajorTopicYN="N">photothermal therapy</Keyword>            <Keyword MajorTopicYN="N">theranostics.</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2018</Year>                <Month>08</Month>                <Day>16</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>12</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>23</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30465497</ArticleId>            <ArticleId IdType="pii">CDM-EPUB-94717</ArticleId>            <ArticleId IdType="doi">10.2174/1389200220666181122105043</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>